2 results
Approved WMOCompleted
Valemetostat tosylate may modify epigenetic changes, which plays an important role in the pathogenesis of PTCL. In the ongoing open-label Phase 1 study (DS3201-A-J101, 25 Dec 2019 data cut-off), valemetostat tosylate monotherapy demonstrated…
Approved WMORecruiting
Explore the clinical feasibility of LED-based PAI of the lymphatic vessels and circulatory system in patients with secondary limb lymphedema.